References

1. https://adisinsight.springer.com/

2. https://www.gsk.com/en-gb/

  1. https://www.reuters.com/legal/transactional/gsk-buy-35pharma-950-million-2026-02-25/
  2. https://companiesmarketcap.com/gbp/glaxo-smith-kline/revenue/#:~:text=Table_title:%20Annual%20revenue%20Table_content:%20header:%20%7C%20Year,%7C%20Revenue:%20%C2%A310.07%20B%20%7C%20Change:%20%7C
  3. https://www.sec.gov/Archives/edgar/data/1131399/000113139925000007/gsk-20241231.htm?utm_source=chatgpt.com
  4. https://business-news-today.com/gsk-q1-2025-earnings-specialty-medicines-power-growth-as-pipeline-builds-investor-confidence/?utm_source=chatgpt.com
  5. https://stockanalysis.com/quote/lon/GSK/revenue/?utm
  6. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-35pharma-inc/?utm
  7. https://www.statnews.com/2026/02/25/gsk-acquires-35pharma-pulmonary-hypertension/#:~:text=The%20company%20said%20HS235%20has,Wood%2C%20GSK's%20chief%20scientific%20officer.
  8. https://www.bitget.com/asia/news/detail/12560605221015?utm
  9. https://www.reuters.com/legal/transactional/gsk-buy-35pharma-950-million-2026-02-25/?utm
  10. https://www.ft.com/content/b2b4743a-3723-44d0-8573-b6eac2f4b10b?utm
  11. https://european-biotechnology.com/latest-news/gsk-buys-35pharma-for-950m-targeting-next-generation-pulmonary-hypertension-therapy-and-the-tgf-%CE%B2-superfamily/?utm
  12. https://www.ad-hoc-news.de/boerse/news/ueberblick/novavax-achieves-profitability-through-strategic-pivot/68616989
  13. https://ir.novavax.com/press-releases/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC10158541/
  15. https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2023.1279710/full
  16. https://ir.novavax.com/press-releases/2016-02-29-Novavax-Reports-Fourth-Quarter-and-Year-End-2015-Financial-Results#:~:text=Novavax%20reported%20a%20net%20loss,became%20reasonably%20assured%20in%202015.
  17. https://www.wallstreetzen.com/stocks/us/nasdaq/nvax/revenue#:~:text=Table_title:%20NVAX%20Revenue%20History%20By%20Year%20Table_content:,$15.35M%20%7C%20NVAX%20Revenue%20Growth:%20%2D57.65%25%20%7C
  18. https://ir.novavax.com/press-releases/2019-03-18-Novavax-Reports-Fourth-Quarter-and-Year-End-2018-Financial-Results#:~:text=Novavax%20revenue%20in%20the%20fourth,for%20same%20period%20in%202017.
  19. https://ir.novavax.com/press-releases/2019-03-18-Novavax-Reports-Fourth-Quarter-and-Year-End-2018-Financial-Results#:~:text=Novavax%20revenue%20in%20the%20fourth,for%20same%20period%20in%202017.
  20. https://stockanalysis.com/stocks/nvax/revenue/
  21. https://ir.novavax.com/press-releases/2020-03-11-Novavax-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results#:~:text=Research%20and%20development%20expenses%20decreased,for%20same%20period%20in%202018.
  22. https://mlq.ai/stocks/NVV1.F/revenue-growth/#:~:text=It's%20a%20crucial%20metric%20for%20evaluating%20a,total%20revenue%20generated%20by%20a%20company:%20Annual
  23. https://www.wallstreetzen.com/stocks/us/nasdaq/nvax/revenue#:~:text=NVAX's%20revenue%20has%20grown%20faster&text=subscribe%20to%20Premium%20to%20read%20more.%20Revenue%20Growth%20vs%20Industry%EF%BB%BF
  24. https://ng.investing.com/pro/NASDAQGS:NVAX/explorer/total_rev
  25. https://mlq.ai/stocks/NVV1.F/revenue-growth/
  26. https://ir.novavax.com/press-releases/2021-03-01-Novavax-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Operational-Highlights#:~:text=The%20increase%20was%20primarily%20due%20to%20increased%20employee%2Drelated%20costs,the%20fourth%20quarter%20of%202020.
  27. https://www.wallstreetzen.com/stocks/us/nasdaq/nvax/revenue#:~:text=Novavax's%20revenue%20for%20the%20twelve,a%202%2C448.48%25%20increase%20from%202019.
  28. https://ir.novavax.com/press-releases/2022-02-28-Novavax-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Operational-Highlights#:~:text=Financial%20Results%20for%20the%20Three,the%20comparable%20periods%20in%202020.
  29. https://www.wallstreetzen.com/stocks/us/nasdaq/nvax/revenue#:~:text=Novavax's%20revenue%20for%20the%20twelve,a%202%2C448.48%25%20increase%20from%202019.
  30. https://ir.novavax.com/press-releases/2023-02-28-Novavax-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Operational-Highlights#:~:text=Total%20revenue%20for%20the%20fourth,the%20same%20period%20in%202021.
  31. https://ir.novavax.com/press-releases/2025-02-27-Novavax-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Operational-Highlights
  32. https://ir.novavax.com/press-releases/2025-02-27-Novavax-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Operational-Highlights
  33. https://ir.novavax.com/press-releases/2026-02-26-Novavax-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights#:~:text=Total%20revenue%20for%20the%20full,for%20the%20full%20year%202024.
  34. https://uk.investing.com/news/stock-market-news/novavax-stock-rises-after-licensing-matrixm-adjuvant-to-pfizer-93CH-4460535?utm_source=chatgpt.com
  35. https://ir.novavax.com/press-releases/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer?utm_source=chatgpt.com
  36. https://news.biobuzz.io/2026/01/20/pfizer-licenses-novavaxs-matrix-m-adjuvant-in-deal-valued-up-to-530m/?utm_source=chatgpt.com
  37. https://www.stocktitan.net/sec-filings/NVAX/8-k-novavax-inc-reports-material-event-e296aa4f2ead.html?utm_source=chatgpt.com
  38. https://www.gilead.com/news/news-details/2026/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel
  39. https://www.bioanalysis-zone.com/gilead-to-buy-arcellx-for-up-to-7-8-billion/
  40. https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-fourth-quarter-and-full-year-2015-financial-results#:~:text=February%202%2C%202016-,Gilead%20Sciences%20Announces%20Fourth%20Quarter%20and%20Full%20Year%202015%20Financial,to%20$24.9%20billion%20for%202014.
  41. https://www.gilead.com/-/media/gileadcorpredesign/pdf/company/annual-esg-reports/gilead_2015_annual_report.pdf
  42. https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-fourth-quarter-and-full-year-2016-financial-results#:~:text=%2D%20Fourth%20Quarter%20Product%20Sales%20of,per%20diluted%20share%20for%202015.
  43. https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-first-quarter-2016-financial-results#:~:text=Total%20product%20sales%20for%20the,the%20U.S.%20in%20November%202015%20.
  44. https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-second-quarter-2016-financial-results#:~:text=8%20and%209.-,Product%20Sales,/tenofovir%20alafenamide%2025%20mg).
  45. https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-fourth-quarter-and-full-year-2017-financial-results#:~:text=%2D%20Fourth%20Quarter%20Product%20Sales%20of,to%20$30.4%20billion%20for%202016.
  46. https://life4me.plus/en/news/gileads-total-revenues-were-26-1-billion-in-2017/#:~:text=Gilead's%20total%20revenues%20were%20$26.1,prescription%20volume%20in%20the%20U.S.
  47. https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-fourth-quarter-and-full-year-2018-financial-results#:~:text=%2D%20Fourth%20Quarter%20Product%20Sales%20of,to%20$26.1%20billion%20for%202017.
  48. https://www.biospace.com/gilead-sciences-announces-fourth-quarter-and-full-year-2018-financial-results#:~:text=For%202018%2C%20HCV%20product%20sales,to%20$3.5%20billion%20in%202017.
  49. https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-fourth-quarter-and-full-year-2019-financial-results#:~:text=For%20the%20fourth%20quarter%20of%202019%2C%20compared,increase%20in%20net%20gains%20from%20equity%20securities.
  50. https://www.indmoney.com/us-stocks/gilead-sciences-inc-share-price-gild
  51. https://www.gilead.com/-/media/files/pdfs/yir-2019-pdfs/2019-gilead-yir_mobile.pdf?la=en&hash=8C8F8A5210EEF2930B186102F3D3EE8F#:~:text=Gilead%20demonstrated%20solid%20financial%20performance,$2.0%20billion%20in%20other%20locations.
  52. https://companiesmarketcap.com/gilead-sciences/revenue/#:~:text=Table_title:%20Annual%20revenue%20Table_content:%20header:%20%7C%20Year,Revenue:%20$22.12%20B%20%7C%20Change:%20%2D15.24%25%20%7C
  53. https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-fourth-quarter-and-full-year-2020-financial-results#:~:text=Trodelvy%C2%AE%20(sacituzumab%20govitecan%2Dhziy,launch%20of%20Veklury%20in%202020.
  54. https://www.wallstreetzen.com/stocks/us/nasdaq/gild/revenue#:~:text=GILD's%20revenue%20has%20grown%20slower&text=subscribe%20to%20Premium%20to%20read%20more.%20Revenue%20Growth%20vs%20Market%EF%BB%BF
  55. https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-fourth-quarter-and-full-year-2021-financial-results
  56. https://www.gilead.com/-/media/gileadcorpredesign/pdf/company/annual-esg-reports/2021-gilead-yir_desktop.pdf
  57. https://s29.q4cdn.com/585078350/files/doc_financials/2021/q4/GILD-Q4-FY-21-Earnings-Press-Release.pdf#:~:text=Product%20Sales%20Performance%20for%20the%20Full%20Year,by%20improved%20treatment%20and%20PrEP%20medication%20demand.
  58. https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-fourth-quarter-and-full-year-2022-financial-results#:~:text=Total%20full%20year%202022%20product,HIV%2C%20Cell%20Therapy%20and%20Trodelvy.
  59. https://s29.q4cdn.com/585078350/files/doc_financials/2022/q4/GILD-Q4-FY22-Earnings-Press-Release-2-February-2023.pdf
  60. https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-fourth-quarter-and-full-year-2023-financial-results#:~:text=period%20in%202022.-,Full%20Year%202023%20Financial%20Results,expenses%2C%20and%20lower%20Veklury%20sales.
  61. https://www.pharmaceutical-technology.com/news/gilead-net-income-fy23/#:~:text=The%20company's%20diluted%20earnings%20per,from%20$3.64%20in%20FY%202022.
  62. https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspx#:~:text=Total%20full%20year%202024%20product,by%20lower%20average%20realized%20price.
  63. https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/v4/GILD-Q424-Earnings-Press-Release-11-February-2025.pdf#:~:text=%E2%80%A2%20Total%20full%20year%202024%20revenue%20increased,offset%20by%20lower%20sales%20of%20Veklury.%20%E2%80%A2
  64. https://www.nasdaq.com/press-release/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results-2025-02#:~:text=Financial%20Results%20%7C%20Nasdaq-,Gilead%20Sciences%20Announces%20Fourth%20Quarter%20and%20Full%20Year%202024%20Financial,quarter%20and%20full%20year%202024.
  65. https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results#:~:text=2025%20Product%20Sales-,Total%20full%20year%202025%20product%20sales%20increased%201%25%20to%20$28.9,demand%20and%20average%20realized%20price.
  66. https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx#:~:text=Total%20full%20year%202025%20revenues,revenues%2C%20and%20lower%20SG&A%20expenses.
  67. https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/revenue#:~:text=Gilead%20Sciences%20revenue%20for%20the,$22.365B
  68. https://www.reuters.com/legal/transactional/gilead-acquire-cancer-therapy-developer-arcellx-up-78-billion-2026-02-23/?utm
  69. https://www.marketwatch.com/story/gilead-shows-its-belief-in-its-partners-cancer-treatment-with-a-7-8-billion-buyout-3f86f10c?utm
  70. https://www.reuters.com/legal/transactional/gilead-acquire-cancer-therapy-developer-arcellx-up-78-billion-2026-02-23/?utm
  71. https://www.tipranks.com/news/ratings/gilead-strategic-arcellx-acquisition-and-anito-cel-pipeline-strength-underpin-buy-rating-and-162-target-ratings-news?
  72. https://cincodias.elpais.com/companias/2026-02-23/gilead-calienta-la-biotecnologia-compra-arcellx-por-6600-millones-para-reforzarse-en-los-tratamientos-de-cancer.html?
  73. https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html
  74. https://www.rttnews.com/3618889/innovent-and-lilly-expand-collaboration-to-advance-global-oncology-immunology-drugs.aspx?
  75. https://www.pharmaceutical-technology.com/news/innovent-lilly-oncology-immunology-medicines/?
  76. https://www.nature.com/articles/nrd4659#:~:text=Publish%20with%20us%20*%20News%20in%20Brief.%20*%20Published:%2001%20June%202015.
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC4489190/
  78. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.33934
  79. https://drug-dev.com/global-immunology-treatment-market-will-exceed-74-billion-by-2022/#:~:text=Market%20News%20&%20Trends-,Global%20Immunology%20Treatment%20Market%20Will%20Exceed%20$74%20Billion%20by%202022,business%20intelligence%20provider%20GBI%20Research.
  80. https://www.scitechnol.com/peer-review/market-analysis-immunology-2020-OuSk.php?article_id=10120
  81. https://www.statista.com/statistics/319284/leading-chemotherapy-and-targeted-cancer-product-revenues-in-us/#:~:text=Other%20statistics%20on%20the%20topic%20%C2%B7%20Leading,market%20revenue%20in%20Peru%20from%202016%20to
  82. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.33934#:~:text=During%20the%20study%20period%2C%20cumulative,001).
  83. https://www.statista.com/statistics/883578/oncology-therapeutic-market-size-growth-by-segment/
  84. https://www.technavio.com/report/global-oncology-solid-tumors-drugs-market#:~:text=Based%20on%20the%20solid%20tumors,provision%20of%20Medicare%20and%20Medicaid.
  85. https://www.pharmaceutical-technology.com/comment/strong-growth-expected-immunology-market-2016-2023/#:~:text=The%20immunology%20drugs%20market%20is,and%20an%20inappropriate%20immune%20response.
  86. https://www.pulsus.com/scholarly-articles/market-analysis-of-international-conference-on-clinical-immunology-and-allergic-diseases.pdf#:~:text=The%20immunology%20medication%20advertises%20is%20anticipated%20to,representing%20half%20of%20the%20worldwide%20immunology%20advertise.
  87. https://uk.finance.yahoo.com/news/oncology-drugs-global-market-opportunities-133300643.html#:~:text=The%20global%20oncology%20drugs%20market,reach%20$445.23%20billion%20in%202032.
  88. https://www.dcatvci.org/features/strong-growth-for-the-oncology-drug-market/#:~:text=Global%20spending%20on%20cancer%20therapies%20and%20supportive%2Dcare,Oncology%20Trends%202018:%20Innovation%2C%20Expansion%20and%20Disruption.
  89. https://idataresearch.com/will-humira-competitors-take-over-the-immunology-drugs-market/#:~:text=In%20a%20new%20series%20of,$1%2C100%20and%20$2%2C600%20per%20month.
  90. https://www.sec.gov/Archives/edgar/data/1704292/000110465920104213/a20-29356_6ex99d1.htm?
  91. https://www.lek.com/sites/default/files/insights/pdf-attachments/2213-Oncology-Success.pdf?
  92. https://www.hengrui.com/images/investor/hk/3.%20Documents%20on%20Display/%28g%29%20Industry%20Report.pdf?
  93. https://www.biospace.com/press-releases/oncology-drugs-market-size-to-reach-usd-366-24-billion-by-2034#:~:text=Advertise-,Oncology%20Drugs%20Market%20Size%20to%20Reach%20USD%20366.24%20Billion%20By,of%20innovative%20therapies%20and%20treatments.
  94. https://www.statista.com/statistics/973523/top-drugs-by-year-on-year-sales-increase/#:~:text=Cancer%20treatments%20are%20becoming%20increasingly,Merck%20expected%20to%20be%20the&text=Merck%20&%20Co.%20has%20seen%20its,to%20maintain%20their%20market%20position.
  95. https://www.globenewswire.com/news-release/2025/12/02/3198196/0/en/Oncology-Market-Size-Worth-USD-668-26-Billion-by-2034.html
  96. https://www.scitechnol.com/peer-review/market-analysis-immunology-2020-OuSk.php?article_id=10120#:~:text=The%20global%20market%20size%20was,other%20parts%20of%20the%20world.
  97. https://www.fortunebusinessinsights.com/press-release/immunology-market-9140?utm
  98. https://www.globenewswire.com/news-release/2021/11/30/2342845/0/en/Immunology-Market-to-Hit-USD-158-69-Billion-by-2028-Immunology-Industry-Size-Share-Growth-Forecast-Report.html
  99. https://finance.yahoo.com/news/immunology-market-size-surpass-usd-090300218.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u
  100. https://finance.yahoo.com/news/immunology-market-size-surpass-usd-112300713.html
  101. https://pharmashots.com/15445/top-20-immunology-companies-based-on-2022-immunology-segment-total-revenue/#:~:text=Top%2020%20Immunology%20Companies%20Based%20on%202022%20Immunology%20Segment%20Total%20Revenue,-ByPrince%20Giri&text=Shots:,2022%20total%20Immunology%20Segment%20Revenue
  102. https://www.fortunebusinessinsights.com/biopharmaceuticals-market-106928#:~:text=Dominated%20the%20Market%20with%20a%20Strong%20Sales%20Performance&text=dominated%20the%20market%20with%20its,USD%203.0%20billion%20by%202030.
  103. https://finance.yahoo.com/news/immunology-market-reach-204-0-104000799.html
  104. https://www.linkedin.com/pulse/immunology-drug-market-size-revenue-smart-automation-opportunities-y7dif/
  105. https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/
  106. https://www.biospace.com/press-releases/immunology-market-poised-for-growth-expected-to-hit-usd-246-04-billion-by-2032-coherent-market-insights#:~:text=Global%20Immunology%20Market%20Key%20Takeaways,increasing%20popularity%20of%20immunology%20therapies.
  107. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-and-full-year-2015-results#:~:text=For%20the%20full%2Dyear%202015%2C%20worldwide%20revenue%20increased,percent%20to%20$19.959%20billion%20compared%20with%202014.
  108. https://www.biospace.com/eli-lilly-reports-fourth-quarter-and-full-year-2015-results#:~:text=In%20the%20fourth%20quarter%20of%202015%2C%20worldwide%20revenue%20was%20$5.376,volumes%20for%20several%20pharmaceutical%20products.
  109. https://investor.lilly.com/static-files/77e65332-ec0d-460e-b29b-2f740617a5b2#:~:text=1.,not%20add%20due%20to%20rounding.&text=ROE%20increased%20in%202016%20as,price%20and%20steady%20dividend%20stream.
  110. https://companiesmarketcap.com/eli-lilly/revenue/#:~:text=Table_title:%20Annual%20revenue%20Table_content:%20header:%20%7C%20Year,Revenue:%20$21.22%20B%20%7C%20Change:%206.33%25%20%7C
  111. https://www.wallstreetzen.com/stocks/us/nyse/lly/revenue#:~:text=Table_title:%20LLY%20Revenue%20History%20By%20Year%20Table_content:,$23.11B%20%7C%20LLY%20Revenue%20Growth:%20+2.25%25%20%7C
  112. https://in.investing.com/news/transcripts/earnings-call-transcript-eli-lillys-q4-2025-results-beat-expectations-93CH-5221899
  113. https://finance.yahoo.com/news/eli-lillys-2025-surge-sets-154900858.html
  114. https://www.alpha-sense.com/earnings/lly/
  115. https://in.investing.com/news/company-news/eli-lilly-q4-2025-slides-revenue-soars-43-as-obesity-treatments-dominate-market-93CH-5221926
  116. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025?
  117. https://intellectia.ai/news/etf/innovent-bio-rises-approximately-6-following-global-partnership-with-eli-lilly?
  118. https://intellectia.ai/news/stock/g-sachs-assigns-buy-rating-to-innovent-bio-following-strengthened-longterm-collaboration-with-eli-lilly?
  119. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0208/2026020800009.pdf?
  120. https://news.futunn.com/en/ja/post/68963847/innovative-drugs-achieve-record-breaking-overseas-expansion-total-bd-in?
  121. https://www.healthcare.digital/single-post/the-2026-biopharmaceutical-m-a-renaissance-strategic-consolidation-amidst-patent-volatility-and-tec?
  122. https://inf.news/en/economy/7353b5d5d8669bb12c9557179d9ac663.html?
  123. https://www.fiercepharma.com/pharma/amid-obesity-push-pfizer-strikes-deal-worth-495m-market-sciwinds-approved-glp-1-china?
  124. https://rollingout.com/2026/02/24/pfizer-strikes-495m-diabetes-deal-china/?
  125. https://vohnetwork.com/news/pharma/pfizer-deepens-metabolic-portfolio-with-495-m-deal-for-sciwinds-ecnoglutide-in-china?
  126. https://www.bloomberg.com/news/articles/2026-02-24/pfizer-secures-china-rights-to-obesity-drug-in-495-million-deal?
  127. https://diabetesjournals.org/diabetes/article/73/Supplement_1/742-P/155871/742-P-A-Phase-3-Evaluation-of-cAMP-Signaling
  128. https://www.sciencedirect.com/science/article/pii/S221385872500141X
  129. https://www.gastroenterologyadvisor.com/news/ecnoglutide-yields-superior-sustained-reduction-in-body-weight/
  130. https://www.sec.gov/Archives/edgar/data/78003/000007800316000077/pfe-12312015x10kexhibit13.htm#:~:text=2015%20Financial%20Report-,Financial%20Review,$3.8%20billion%2C%20or%208%25.
  131. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2015/performance.htm#:~:text=for%20launched%20medicines%20in%20markets%20that%20have%20a%20GDP%20per%20capita%20less%20than%20Portugal.&text=Adjusted%20Revenues%2C%20Adjusted%20Cost%20of%20Sales%2C%20Adjusted%20Selling%2C%20Informational
  132. https://s206.q4cdn.com/795948973/files/doc_financials/2015/q4/Q4_2015_PFE_Earnings_Press_Release_asdlkfsdaf.pdf
  133. https://www.sec.gov/Archives/edgar/data/78003/000007800317000014/pfe-12312016x10kexhibit13.htm#:~:text=this%20Financial%20Review).-,Our%202016%20Performance,of%20foreign%20exchange%20of%203%25.
  134. https://s206.q4cdn.com/795948973/files/doc_financials/2016/q4/Q4_2016_PFE_Earnings_Press_Release_dwerfks.pdf
  135. https://s206.q4cdn.com/795948973/files/doc_financials/2016/q4/Q4_2016_PFE_Earnings_Press_Release_dwerfks.pdf
  136. https://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit13x12312017x10k.htm?itid=lk_inline_enhanced-template#:~:text=Revenues%20in%202017%20decreased%20by%20$278%20million%2C,million%2C%20or%20less%20than%201%25%2C%20and%20an
  137. https://s206.q4cdn.com/795948973/files/doc_financials/2017/q4/Q4_2017_PFE_Earnings_Release.pdf
  138. https://s206.q4cdn.com/795948973/files/doc_financials/2018/q4/Q4-2018-PFE-Earnings-Release.pdf
  139. https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-12312018x10kshell.htm
  140. https://companiesmarketcap.com/pfizer/revenue/#:~:text=Table_title:%20Annual%20revenue%20Table_content:%20header:%20%7C%20Year,Revenue:%20$53.64%20B%20%7C%20Change:%202.1%25%20%7C
  141. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2020-results?
  142. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2020-results?
  143. https://www.cnbc.com/2023/01/31/the-covid-pandemic-drives-pfizers-2022-revenue-to-a-record-100-billion.html?
  144. https://www.cnbc.com/2024/06/28/pfizer-stock-employees-covid-recovery.html?
  145. https://www.cfobrew.com/stories/2024/01/31/pfizer-had-a-rough-2023?
  146. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2023/?
  147. https://www.cnbc.com/2023/01/31/the-covid-pandemic-drives-pfizers-2022-revenue-to-a-record-100-billion.html?
  148. https://br.advfn.com/noticias/PRNUS/2026/artigo/97896881?
  149. https://www.biospace.com/deals/pfizer-builds-global-glp-1-strategy-with-up-to-495m-sciwind-deal?
  150. https://www.biospace.com/deals/pfizer-builds-global-glp-1-strategy-with-up-to-495m-sciwind-deal?
  151. https://br.advfn.com/noticias/PRNUS/2026/artigo/97896881?
  152. https://br.advfn.com/noticias/PRNUS/2026/artigo/97896881?
  153. https://www.biospace.com/deals/pfizer-builds-global-glp-1-strategy-with-up-to-495m-sciwind-deal?
  154. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing
  155. https://maqs.com/en/news/maqs-advised-ribocure-global-licensing-agreement-madrigal
  156. https://www.bioworld.com/keywords/48829-ribocure-pharmaceuticals-ab
  157. https://biopharmaapac.com/news/28/7575/ribo-and-ribocure-sign-global-licensing-deal-with-madrigal-for-six-sirna-programmes-in-mash.html
  158. https://www.prnewswire.com/news-releases/ribo-and-ribocure-announce-exclusive-global-licensing-agreement-with-madrigal-for-novel-sirna-therapeutics-targeting-mash-302685038.html
  159. https://ribocure.com/science/#:~:text=Efficient%20and%20specific%20delivery%20of,with%20origin%20in%20the%20liver.
  160. https://www.ribolia.com/en/media-center/our-products-news/45#:~:text=D.%2C%20Senior%20Vice%20President%20and,that%20exceeds%20USD%202%20billion.
  161. https://www.europeanpharmaceuticalreview.com/news/190590/boehringer-ingelheim-agrees-2bn-sirna-therapeutic-collaboration/#:~:text=Boehringer%20Ingelheim's%20recent%20M&A%20activity,therapies%20in%20one%20single%20agent.
  162. https://www.ribolia.com/en/media-center/our-products-news/22#:~:text=RBD7022%20is%20the%205th%20drug%20product%20that,has%20become%20mature%E2%80%9D%2C%20said%20Zicai%20Liang%2C%20Ph.
  163. https://pharmaphorum.com/news/boehringer-targets-nashmash-2bn-ribo-alliance#:~:text=Ribo%20is%20working%20on%20small%2C%20interfering%20RNA,some%20that%20were%20%E2%80%9Cpreviously%20inaccessible%E2%80%9D%2C%20said%20Boehringer.
  164. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year#:~:text=Total%20revenues:%20The%20Company%20generated,offset%20by%20increases%20in%20headcount.
  165. https://www.tradingview.com/news/tradingview:fd8986d7f6337:0-madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results/#:~:text=Madrigal%20Pharmaceuticals%2C%20Inc.%2C%20a,headcount%20and%20stock%20compensation%20expenses.
  166. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0#:~:text=Total%20Revenues%3A%20Madrigal%20generated%20fourth,million%20and%20%24180.1%20million%20%2C%20respectively.
  167. https://www.industryarc.com/Research/NASH-Market-Research-503731#:~:text=NASH%20Market%20is%20estimated%20to,also%20contributed%20to%20market%20growth.
  168. https://www.giiresearch.com/report/tbrc1833956-mash-treatment-global-market-opportunities.html#:~:text=The%20global%20MASH%20treatment%20market,)%20of%20more%20than%2021.00%25.
  169. https://news.futunn.com/en/post/50918781/new-stock-preview-with-over-cny-1-billion-in-accumulated?
  170. https://www.biospace.com/non-alcoholic-steatohepatitis-treatment-market-size-report-2022-2030?
  171. https://www.globenewswire.com/de/news-release/2025/11/27/3195540/28124/en/7MM-Metabolic-Dysfunction-Associated-Steatohepatitis-Drug-Analysis-and-Forecast-Report-2022-2032-Growth-Driven-by-GLP-1RA-Launches-Such-as-Semaglutide-and-Rising-Adoption-of-Non-In.html
  172. https://www.prnewswire.com/news-releases/nashmash-treatment-market-to-surpass-usd-31-76-billion-by-2033-as-first-in-class-drugs-redefine-fatty-liver-disease-management--according-to-datam-intelligence-302621570.html?
  173. https://www.biospace.com/non-alcoholic-steatohepatitis-treatment-market-size-report-2022-2030?
  174. https://www.pharmaceutical-technology.com/analyst-comment/mash-revival-innovator-drug-partnership-deals-in-2024/?cf-view
  175. https://pmc.ncbi.nlm.nih.gov/articles/PMC12830047/
  176. https://www.industryarc.com/Research/NASH-Market-Research-503731#:~:text=NASH%20Market%20is%20estimated%20to,also%20contributed%20to%20market%20growth.
  177. https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors
  178. https://www.fiercebiotech.com/biotech/abbvie-pens-56b-pact-remegen-join-pd1xvegf-bispecific-battle
  179. https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-2015-and-fourth-quarter-financial#:~:text=%2D%20Reports%20Full%2DYear%20Adjusted%20EPS,Double%2DDigit%20Growth%20Versus%202015
  180. https://www.statista.com/statistics/417030/revenue-of-abbvie/
  181. https://news.abbvie.com/2025-10-31-AbbVie-Reports-Third-Quarter-2025-Financial-Results?
  182. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-10-14-00-56-3235419
  183. https://www.bioanalysis-zone.com/sanofi-snaps-up-dynavax-in-us-2-2b-deal/
  184. https://chemanager-online.com/en/news/sanofi-completes-acquisition-of-dynavax
  185. https://www.ema.europa.eu/en/medicines/human/EPAR/heplisav-b
  186. https://www.hepb.org/prevention-and-diagnosis/vaccination/guidelines-2/
  187. https://www.heplisavb.com/#:~:text=Heplisav%2DB%20is%20a%20hepatitis%20B%20vaccine%20that,Adults%20with%20a%20history%20of%20HBV%20infection
  188. https://pmc.ncbi.nlm.nih.gov/articles/PMC12792159/
  189. https://www.multivu.com/players/English/7753751-sanofi-2015-annual-results/docs/presentation-888858023.pdf
  190. https://www.prnewswire.com/news-releases/sanofi-delivered-2015-business-eps-up-85-on-a-reported-basis-and-stable-at-constant-exchange-rates-consistent-with-guidance-300217264.html
  191. https://www.news.sanofi.us/index.php?s=35142&item=1164#:~:text=Table_title:%20Photos%20&%20Videos%20Table_content:%20header:%20%7C,Q4%202016:%20%E2%82%AC1.25%20%7C%202016:%20%E2%82%AC5.68%20%7C
  192. https://www.prnewswire.com/news-releases/sanofi-delivers-2016-sales-and-business-eps-growth-at-cer-300404158.html#:~:text=Net%20sales%20in%202016%20were,up%207.0%25%20excluding%20Venezuela).
  193. https://www.statista.com/statistics/266509/revenue-of-sanofi-since-2006/#:~:text=Table_title:%20Revenue%20of%20Sanofi%20from%202006%20to,%7C%20Revenue%20in%20million%20euros:%2030%2C693%20%7C
  194. https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm?
  195. https://www.tradingview.com/news/invezz%3Ade59e79f8094b%3A0-sanofi-to-acquire-dynavax-for-2-2b-sending-shares-higher-by-37/?
  196. https://www.marketscreener.com/news/sanofi-set-to-acquire-dynavax-technologies-ce7e59dadb8bfe27?
  197. https://www.ainvest.com/aime/share/sanofi-acquires-dynavax-22b-sectors-benefit-ma-trend-3ce0e1/?
  198. https://firstwordpharma.com/story/7086594
  199. https://www.wsj.com/health/pharma/astrazeneca-strikes-multibillion-dollar-obesity-deal-with-chinas-cspc-81830497
  200. https://xtalks.com/astrazeneca-seals-1-2b-obesity-and-metabolic-disease-pipeline-deal-with-cspc-pharma-4626/
  201. https://www.reddit.com/user/krishna_2020/comments/r12e9p/antiobesity_market_latest_trends_and_business/?
  202. https://zipdo.co/obesity-drug-industry-statistics/?
  203. https://www.globenewswire.com/news-release/2022/08/22/2502015/0/en/Global-Anti-Obesity-Drugs-Market-is-projected-to-reach-a-market-value-of-US-11-079-1-Million-by-2031-Visiongain-Reports-Ltd.html
  204. https://www.globenewswire.com/news-release/2023/08/16/2726217/0/en/Anti-obesity-Drugs-Market-Size-to-Surpass-USD-22-85-billion-by-2030-exhibiting-a-CAGR-of-26-1.html
  205. https://www.globenewswire.com/news-release/2025/11/27/3195649/0/en/Anti-Obesity-Drugs-Market-Size-to-Reach-35-52-Billion-by-2032-Driven-by-Advancements-in-Weight-Management-Therapies-and-Rising-Obesity-Prevalence-SNS-Insider.html
  206. https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783?
  207. https://www.theinsightpartners.com/reports/anti-obesity-drugs-market
  208. https://meditechinsights.com/global-obesity-drugs-market/
  209. https://www.globenewswire.com/news-release/2023/10/25/2766377/0/en/Diabetes-Drugs-Market-Size-to-Surpass-USD-134-08-Billion-by-2030-exhibiting-a-CAGR-of-7-8.html
  210. https://www.globenewswire.com/news-release/2025/02/10/3023509/0/en/Diabetes-Drug-Market-Size-to-Surpass-USD-145-Billion-by-2032-at-a-CAGR-of-6-9-Fueled-by-Rising-Global-Diabetes-Prevalence-SNS-Insider.html
  211. https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015.html#:~:text=Highlights%20*%20Emerging%20Markets%20revenue%20grew%20by,$2%2C020%20million.%20*%20Opened%20facility%20in%20Russia.
  212. https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2015/AZ_Annual_Report_2015(1).pdf#:~:text=Total%20Revenue*%20up%201%25%20at%20CER%20to,actual%20rate%20of%20exchange)%20to.%20$3%2C324%20million.
  213. https://www.sec.gov/Archives/edgar/data/901832/000095010316011733/dp64063_ex1501.htm#:~:text=The%20three%2Dyear%20detailed%20business%20plan%20captures%20risks,is%20used%20to%20perform%20central%20net%20debt
  214. https://www.astrazeneca.com/content/dam/az/PDF/2016/AZ_In_Brief_2015.pdf
  215. https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016.html#:~:text=Cardiovascular%20&%20Metabolic%20Disease-,$8%2C116m,m%2C%202014:%20$9%2C802m)
  216. https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2017.html#:~:text=%E2%80%A2%202%25%20decrease%20in%20Total,%25%20(12%25%20at%20CER)
  217. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2017/annualreport2017.pdf
  218. https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2018.html#:~:text=EPS-,Revenue%20and%20Cash,$2.6bn
  219. https://www.astrazeneca.com/content/dam/az/PDF/2018/full-year/Full-Year_2018_Results_announcement.pdf
  220. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2018/PDF/AstraZeneca_AR_2018.pdf
  221. https://www.astrazeneca.com/content/dam/az/PDF/2019/full-year/Full-year_and_Q4_2019_results_announcement.pdf
  222. https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2019.html#:~:text=Revenue%20and%20Cash,pipeline%20and%20returned%20to%20growth.
  223. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2019/pdf/AstraZeneca_AR_2019.pdf
  224. https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2020.html#:~:text=05-,Financial%20Highlights,EPS
  225. https://www.cnbc.com/2021/02/11/astrazeneca-sales-rise-10percent-in-a-year-dominated-by-the-coronavirus.html#:~:text=The%20Anglo%2DSwedish%20pharmaceutical%20giant,%2C%22%20said%20CEO%20Pascal%20Soriot.
  226. https://www.astrazeneca.com/content/dam/az/PDF/2021/full-year/Full-year-2021-results-announcement.pdf
  227. https://www.pharmaceutical-technology.com/news/astrazeneca-fy-2021-revenue/#:~:text=Total%20revenue%20for%20the%20Covid,by%2026%25%20to%20$33.44bn.
  228. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2022/pdf/AstraZeneca_AR_2022.pdf
  229. https://www.macrotrends.net/stocks/charts/AZN/astrazeneca/revenue#:~:text=AstraZeneca%20annual%20revenue%20for%202022,a%2018.53%25%20increase%20from%202021.
  230. https://companiesmarketcap.com/astrazeneca/revenue/#:~:text=Table_title:%20Annual%20revenue%20Table_content:%20header:%20%7C%20Year,Revenue:%20$26.61%20B%20%7C%20Change:%209.16%25%20%7C
  231. https://www.astrazeneca.com/content/dam/az/PDF/2025/Q4-FY/Full-year-Q4-2025-results-announcement.pdf
  232. https://in.investing.com/news/company-news/astrazeneca-q4-and-fy-2025-slides-8-revenue-growth-strategic-investments-for-2030-93CH-5232195
  233. https://investingnews.com/astrazeneca-results-fy-and-q4-2025/#:~:text=Table_title:%20AstraZeneca%20results:%20FY%20and%20Q4%202025,2025:%206.60%20%7C%20Q4%202025:%201.50%20%7C
  234. https://www.morningstar.com/news/alliance-news/1769766897802191300/astrazeneca-strikes-obesity-deal-with-chinas-cspc-pharmaceuticals?
  235. https://www.indianpharmapost.com/news/lite/astrazeneca-expands-obesity-and-diabetes-pipeline-with-12b-cspc-deal-19010?
  236. https://www.pharmexec.com/view/astrazeneca-enters-4-billion-collaboration-agreement-cspc?
  237. https://www.pharmatutor.org/pharma-news/2026/astrazeneca-taps-cspc-to-supercharge-obesity-and-type-2-diabetes-pipeline?
  238. https://www.directorstalkinterviews.com/astrazeneca-signs-1-2bn-obesity-drug-collaboration-with-cspc/4121237418?
  239. https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-cspc-pharmaceutical-inks-deal-with-astrazeneca-weight-loss-therapy-2026-01-30/?
  240. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/
  241. https://www.dcatvci.org/top-industry-news/gsk-completes-2-2-bn-acquisition-of-rapt-therapeutics/
  242. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-rapt-therapeutics/
  243. https://in.investing.com/news/company-news/gsk-completes-22-billion-acquisition-of-rapt-therapeutics-93CH-5269751
  244. https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-9a7a0d935a69.html
  245. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/
  246. https://www.dcatvci.org/top-industry-news/gsk-completes-2-2-bn-acquisition-of-rapt-therapeutics/
  247. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-rapt-therapeutics/
  248. https://investors.rapt.com/node/10781/pdf#:~:text=About%20Ozureprubart%20(formerly%20RPT904),first%20generation%20anti%2DIgE%20mAb.
  249. https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-initiates-prestige-phase-2b-clinical-trial
  250. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-rapt-therapeutics/
  251. https://investors.rapt.com/static-files/5e90d821-377d-4b8a-ab4d-24768e266c56
  252. https://www.pharmanow.live/latest-news/rapt-begins-phase-2b-trial-ozureprubart-food-allergies
  253. https://www.prnewswire.com/news-releases/scineuro-and-novartis-enter-into-a-licensing-and-collaboration-agreement-for-next-generation-therapeutics-to-treat-alzheimers-disease-302658400.html
  254. https://www.pharmaceutical-technology.com/news/scineuro-novartis-global-licensing-deal/
  255. https://global.pharmcube.com/news/detail/17b275a45c444fec8a747804e308dca1?type=dailyNews
  256. https://finance.yahoo.com/news/sino-biopharmaceutical-buys-drugmaker-hangzhou-102631693.html
  257. https://finance.yahoo.com/news/sino-biopharmaceutical-buys-drugmaker-hangzhou-102631693.html
  258. https://firstwordpharma.com/story/7064296
  259. https://www.reddit.com/r/Inovio/comments/1qq2pr4/january_28_2026_shanghai_china_orient_strategy/?utm_source=chatgpt.com&rdt=63985
  260. https://news.futunn.com/en/post/68305524/kanghua-bio-300841-plans-staged-acquisition-of-nameixin-to-strengthen?level=2&data_ticket=1771303572485422
  261. http://media.drugdu.com/ddu-news/core-patent-barriers-hard-to-breach-kanghua-biologics-faces-formidable-challenges-in-mrna-vaccine-development.html
  262. https://www.indexbox.io/blog/fosun-pharmas-henlius-strikes-155b-cancer-drug-deal-with-japans-eisai/#:~:text=A%20unit%20of%20Fosun%20Pharma%20has%20struck,Japan's%20Eisai%2C%20adding%20to%20a%20wave%20of
  263. https://www.pressreader.com/china/south-china-morning-post-6150/20260211/282037628609899
  264. https://www.scmp.com/business/china-business/article/3342652/fosun-pharmas-us155-billion-eisai-deal-signals-shift-long-term-partnerships?utm_source=rss_feed
  265. https://www.scmp.com/business/banking-finance/article/3340932/chinas-fosun-pharma-eyes-spin-listing-vaccine-unit-hot-hong-kong-ipo-market
  266. https://www.medilinkthera.com/news-details/52
  267. https://www.prnewswire.com/news-releases/medilink-has-signed-an-additional-exclusive-licensing-agreement-with-roche-302656495.html
  268. https://www.fiercebiotech.com/biotech/roche-returns-medilink-promise-570m-near-term-payments-another-adc
  269. https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Announces-Collaboration-and-Exclusive-Worldwide-License-Agreement-with-Bristol-Myers-Squibb-to-Develop-a-Novel-Tumor-Activated-Therapeutic-for-Solid-Tumors/default.aspx
  270. https://ehealth.eletsonline.com/2026/01/janux-therapeutics-bristol-myers-squibb-enter-up-to-850-million-cancer-drug-deal/#:~:text=Under%20the%20agreement%2C%20Bristol%20Myers,latest%20insights!%22%20Click%20here!
  271. https://www.precisionmedicineonline.com/precision-oncology/janux-therapeutics-licenses-tumor-activated-cancer-therapeutic-bms-potential
  272. https://www.fiercebiotech.com/biotech/bms-pens-850m-solid-tumor-pact-t-cell-engager-biotech-janux#:~:text=The%20collaboration%20with%20Janux%20includes:%20*%20**Human,transformative%20therapies%20to%20patients%20with%20difficult%2Dto%2Dtreat%20cancers**
  273. https://b2b.economictimes.indiatimes.com/news/entrepreneur/usv-pharma-buys-79-stake-in-wellbeing-nutrition-for-1583-crore/128266697#:~:text=USV%20Pharma%20buys%2079%25%20stake,for%20%E2%82%B91%2C583%20crore%2C%20EconomictimesB2B
  274. https://www.reuters.com/business/healthcare-pharmaceuticals/frontier-biotechnologies-strikes-up-1-billion-deal-with-gsk-2026-02-24/
  275. https://www.fiercebiotech.com/biotech/takeda-inks-17b-ai-discovery-deal-iambic-therapeutics
  276. https://www.biopharmadive.com/news/lilly-deal-csl-100m-license-monoclonal-antibody-targeting-il-6/812455/
  277. https://www.biopharmadive.com/news/novartis-avidity-acquire-deal-rna-drugs-neuromuscular-disease/803817/
  278. https://www.citybiz.co/article/763681/novartis-to-acquire-avidity-biosciences-in-12-billion-bet-on-rare-disease-drug/#:~:text=Novartis%20AG%20said%20Sunday%20it,at%20other%20severe%20muscle%20conditions.
  279. https://www.fiercebiotech.com/biotech/lilly-pens-11b-pact-german-biotech-work-gene-editing-med-hearing-loss
  280. https://www.businesswire.com/news/home/20260106591786/en/Cartography-Biosciences-and-Pfizer-to-Collaborate-on-the-Discovery-of-Tumor-Selective-Antigens
  281. https://www.pharmafocuseurope.com/news/cartography-biosciences-and-pfizer-collaborate-to-identify#:~:text=Cartography%20Biosciences%2C%20Inc.%2C%20a,combinations%20with%20strong%20tumour%20selectivity.
  282. https://www.drugdiscoverytrends.com/2025-pharma-ma-surges-to-70-billion/?utm_source=chatgpt.com
  283. https://www.statista.com/statistics/314605/global-pharmaceutical-merger-and-acquisition-deals/?utm_source=chatgpt.com
  284. https://www.globenewswire.com/en/news-release/2025/08/08/3129959/28124/en/M-A-Trends-in-Pharma-Report-Q2-2025-Deals-Fall-to-32-9-Billion-in-Q2-2025-with-Oncology-Leading-at-51-Transactions.html
  285. https://www.expresspharma.in/pharma-and-healthcare-deals-in-q1-2025-remain-stable-amid-shift-to-scalable-global-models/?utm_source=chatgpt.com
  286. https://www.pwc.com/gx/en/services/deals/trends/2025.html?utm_source=chatgpt.com
  287. https://redbock.com/news/life-sciences-m-a-outlook/?
  288. https://dealforma.com/global-healthcare-and-life-sciences-q1-2025-review/?
  289. https://dealforma.com/healthcare-and-life-sciences-quarterly-overview-q2-2025/?
  290. https://dealforma.com/healthcare-and-life-sciences-quarterly-overview-q3-2025/?
  291. https://www.globenewswire.com/news-release/2026/01/14/3218726/0/en/Healthcare-Quarterly-M-A-Volume-Decreases-in-Q4-25-According-to-Acquisition-Data-from-LevinPro-HC.html
  292. https://www.expertmarketresearch.com/healthcare-articles/healthcare-biotechnology-mergers-and-acquisitions-outlook?
  293. https://www.barrons.com/articles/verona-pharma-stock-merck-acquisition-3c2bc32c?
  294. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/torrent-pharma-to-acquire-jb-chemicals-at-rs-25689-crore-valuation/articleshow/122147164.cms?
  295. https://www.forbes.com/sites/innovationrx/2025/11/19/big-pharma-has-spent-nearly-150-billion-on-ma-so-far-in-2025/?
  296. https://www.biospace.com/business/five-biggest-biopharma-takeovers-of-2025?
  297. https://pharma.nridigital.com/pharma_jan26/biopharmas-2025-ma-boom-dealmaking-surges-as-patent-pressures-intensify?
  298. https://www.williamblair.com/~/media/Downloads/IB/2025/williamblair-2024_biopharma_quarterly_review_january_2025.pdf?
  299. https://visionlifesciences.com/insights/biotech-licensing-deal-tracker-2026?
  300. https://www.reuters.com/business/healthcare-pharmaceuticals/roche-develop-commercialize-obesity-drug-with-zealand-pharma-2025-03-12/?
  301. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ichnos-glenmark-abbvie-ink-usd-2-bn-licensing-deal-for-commercialisation-of-investigational-asset/articleshow/122369541.cms?
  302. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-signs-up-21-billion-licensing-deal-with-omeros-rare-disease-push-2025-10-15/?
  303. https://dealforma.com/large-cap-biopharma-in-licensing-and-buying-2024-q2-2025/?
  304. https://visionlifesciences.com/insights/biotech-licensing-deal-tracker-2026?
  305. https://dealforma.com/global-healthcare-and-life-sciences-rd-partnerships-2025-review/?
  306. https://www.ft.com/content/6acff1e0-e23e-4a46-a232-9da44ef2d5dd?
  307. https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?
  308. Eikon Therapeutics pricing press release (Feb 4, 2026) — https://investors.eikontx.com/news-releases/news-release-details/eikon-therapeutics-announces-pricing-upsized-initial-public
  309. Fierce Biotech: Eikon upsized $381M listing marks largest biotech IPO since 2024 (Feb 5, 2026) — https://www.fiercebiotech.com/biotech/eikons-upsized-381m-nasdaq-listing-marks-largest-biotech-ipo-2024
  310. Generate Biomedicines pricing PR (Feb 26, 2026) — https://www.prnewswire.com/news-releases/generate-biomedicines-inc-announces-pricing-of-initial-public-offering-302699146.html
  311. Goodwin: Generate IPO closing (Mar 4, 2026) — https://www.goodwinlaw.com/en/news-and-events/news/2026/03/announcements-lifesciences-goodwin-advises-generate-biomedicines
  312. Aktis Oncology IPO closing PR (Jan 13, 2026) — https://investors.aktisoncology.com/news-releases/news-release-details/aktis-oncology-announces-closing-upsized-initial-public-offering
  313. U.S. News / Reuters: Aktis prices upsized US IPO at $18 (Jan 8, 2026) — https://money.usnews.com/investing/news/articles/2026-01-08/aktis-oncology-prices-upsized-us-ipo-at-18-per-share
  314. SpyGlass Pharma pricing PR (Feb 5, 2026) — https://ir.spyglasspharma.com/news-releases/news-release-details/spyglass-pharma-announces-pricing-initial-public-offering
  315. Agomab Therapeutics IPO pricing (Feb 5, 2026) — https://agomab.com/wp-content/uploads/2026/02/20260205_Agomab-Announces-Pricing-of-Initial-Public-Offering_Final.pdf
  316. Fierce Biotech Fundraising Tracker ’26 (March entries) — https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-26
  317. Xtalks: Biotech Funding 2026 Tracker (Mar 9, 2026) — https://xtalks.com/biotech-funding-2026-tracker-latest-raises-rounds-and-rd-momentum-4596/
  318. Labiotech.eu: 2026 Biotech funding tracker — https://www.labiotech.eu/biotech-funding-2026-tracker/
  319. NIH Guide: Notice of Fiscal Policies for FY 2026 (Mar 18, 2026) — https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-059.html
  320. Gates Foundation grant to BioNTech (Jan/Feb 2026) — https://www.gatesfoundation.org/about/committed-grants/2026/02/inv-065078
  321. Gates Foundation grant to IVI (Jan/Feb 2026) — https://www.gatesfoundation.org/about/committed-grants/2026/02/inv-099776
  322. CEPI: Calls for Proposals (accessed Mar 2026) — https://cepi.net/calls-for-proposals

Pharma Insight Reports

https://adisinsight.springer.com/insight-hub